Phase I trial of ixabepilone plus pegylated liposomal doxorubicin in patients with adenocarcinoma of breast or ovary

Chuang, Ellen; Wiener, N.; Christos, Paul J.; Kessler, Romain; Cobham, Marta Vallee; Donovan, Diana; Goldberg, Gary L.; Caputo, Thomas A.; Doyle, Austin; Vahdat, Linda T.; Sparano, Joseph A.

doi:10.1093/annonc/mdq080

Cited by 10 publications

(14 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…With regard to ixabepilone, eleven studies (125 patients) were identified, 19 , 20 , 23 , 25 – 27 , 30 – 32 , 36 , 38 nine described the results of Phase I trials, 19 , 23 , 25 – 27 , 30 , 31 , 36 , 38 and two the results of nonrandomized Phase II trials. 20 , 32 One trial dealt with platinum-refractory or -resistant epithelial ovarian cancer and primary fallopian or primary peritoneal cancer, 20 while in the remaining studies no detailed data were provided.…”

Section: Resultsmentioning

confidence: 99%

“… 20 , 32 One trial dealt with platinum-refractory or -resistant epithelial ovarian cancer and primary fallopian or primary peritoneal cancer, 20 while in the remaining studies no detailed data were provided. 19 , 23 , 25 – 27 , 30 – 32 , 36 , 38 Moreover, ixabepilone has been evaluated as monotherapy, 20 , 25 – 27 , 30 – 32 , 36 , 38 as well as in combination with gemcitabine 23 and pegylated liposomal doxorubicin (PLD). 19 Clinical data regarding ixabepilone have presented promising results, with a clinical benefit rate ranging between 0 and 100%.…”

Section: Resultsmentioning

confidence: 99%

“… 19 , 23 , 25 – 27 , 30 – 32 , 36 , 38 Moreover, ixabepilone has been evaluated as monotherapy, 20 , 25 – 27 , 30 – 32 , 36 , 38 as well as in combination with gemcitabine 23 and pegylated liposomal doxorubicin (PLD). 19 Clinical data regarding ixabepilone have presented promising results, with a clinical benefit rate ranging between 0 and 100%. 19 , 20 , 23 , 25 – 27 , 30 – 32 , 36 , 38 Data regarding PFS and/or OS were reported in four trials (OS 28.4–14.8 months; disease-free survival 7.1–4.1 months).…”

Section: Resultsmentioning

confidence: 99%

“… 19 Clinical data regarding ixabepilone have presented promising results, with a clinical benefit rate ranging between 0 and 100%. 19 , 20 , 23 , 25 – 27 , 30 – 32 , 36 , 38 Data regarding PFS and/or OS were reported in four trials (OS 28.4–14.8 months; disease-free survival 7.1–4.1 months). 19 , 20 , 30 , 31 All studies reported outcomes pertaining to efficacy and/or safety.…”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Epothilones in epithelial ovarian, fallopian tube, or primary peritoneal cancer: a systematic review

Zagouri¹,

Sergentanis²,

Chrysikos³

et al. 2015

OTT

View full text Add to dashboard Cite

Ovarian cancer is the most lethal gynecologic malignancy; consequently, there is a need for effective therapies. Epothilones are microtubule-stabilizing agents that inhibit cell growth. Currently, patupilone and its four synthetic derivatives ixabepilone, BMS-310705, sagopilone, 20-desmethyl-20-methylsulfanyl epothilone B and epothilone D, as well as its derivative KOS-1584, are under clinical evaluation. This is the first systematic review conducted in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines that synthesizes all available data emerging from trials and evaluates the efficacy and safety of epothilones in epithelial ovarian, primary fallopian tube, and primary peritoneal cancer. Despite the fact that epothilones have proven active in taxane-resistant settings in preclinical models, it is not yet clear from Phase II/III studies reviewed here that their clinical activity is superior to that of taxanes. Nevertheless, responses to epothilones have been observed in platinum-refractory/resistant ovarian cancer patients. Moreover, despite the shared mechanism of action of epothilones, their clinical profile seems clearly different, with diarrhea being the most common dose-limiting toxicity encountered with patupilone, whereas neutropenia and sensory neuropathy are the most common toxic effects observed with the other epothilones. In any case, randomized trials comparing epothilones with standard treatments seem warranted to define further the role of these agents, whereas biomarker analysis might further optimize patient selection.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Epothilones in epithelial ovarian, fallopian tube, or primary peritoneal cancer: a systematic review

Zagouri¹,

Sergentanis²,

Chrysikos³

et al. 2015

OTT

View full text Add to dashboard Cite

show abstract

“…Однако механиз-мы, с помощью которых происходит связывание с этими доменами, различны [28]. Поэтому иксабепилон поддер-живает активность против устойчивых к паклитакселу клеточных линий [29,30]. Кроме того, иксабепилон пока-зал выраженную активность на модели ксенотрансплан-тата с избыточной экспрессией βIII-тубулина (Pat-21 при раке молочной железы) и на двух моделях ксенотран-сплантата с повышенной экспрессией переносчиков оттока лекарственных препаратов (Pat-7 при раке яични-ков и HCTVM46 при раке толстой кишки) [31,32].…”

Section: показания к применению иксабепилонаunclassified

New Advances in the Treatment of Breast Cancer: The Role Epothilones

Семиглазова¹,

Клюге²,

Коробейникова³

et al. 2017

Med. sov.

View full text Add to dashboard Cite

Beyond taxanes: the next generation of microtubule-targeting agents

Cortés

Vidal

2011

Breast Cancer Res Treat

View full text Add to dashboard Cite

Taxanes are a standard first-line option for metastatic breast cancer (MBC), but their utility may be limited by primary or acquired resistance. New microtubule-targeting agents have been developed to overcome taxane resistance and provide additional options for improving patient outcomes. This article reviews these alternative microtubule-targeting agents and their potential clinical benefits for MBC patients. Relevant clinical data were compiled through searches within PubMed and congress abstract databases. Ixabepilone, a novel microtubule-stabilizing drug approved by the US Food and Drug Administration (FDA), has proven efficacy across multiple lines of therapy, including patients with taxane-resistant/refractory disease. In phase III trials, ixabepilone plus capecitabine significantly improved progression-free survival compared with capecitabine alone in anthracycline/taxane-pretreated patients. Eribulin has recently been approved by the FDA and by the European Medicines Agency for the treatment of patients with MBC who have received at least two prior chemotherapy regimens for late-stage disease. In a phase III trial, eribulin extended overall survival compared with the physician’s treatment choice in heavily pretreated MBC patients. In addition, several investigational microtubule-targeting agents may have therapeutic potential in MBC. The development of new microtubule-targeting agents helps to address the need for additional effective regimens for patients progressing after standard treatment with anthracycline- and taxane-containing regimens.

show abstract

Phase I trial of ixabepilone plus pegylated liposomal doxorubicin in patients with adenocarcinoma of breast or ovary

Cited by 10 publications

References 26 publications

Epothilones in epithelial ovarian, fallopian tube, or primary peritoneal cancer: a systematic review

Epothilones in epithelial ovarian, fallopian tube, or primary peritoneal cancer: a systematic review

New Advances in the Treatment of Breast Cancer: The Role Epothilones

Beyond taxanes: the next generation of microtubule-targeting agents

Contact Info

Product

Resources

About